
## Manuela Ludovisi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5845151/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer. Journal of Clinical Oncology, 2008, 26, 890-896.	1.6	259
2	Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound in Obstetrics and Gynecology, 2008, 31, 560-566.	1.7	144
3	Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecologic Oncology, 2005, 96, 729-735.	1.4	129
4	Imaging in gynecological disease (1): ultrasound features of metastases in the ovaries differ depending on the origin of the primary tumor. Ultrasound in Obstetrics and Gynecology, 2007, 29, 505-511.	1.7	102
5	Transvaginal ultrasonography and magnetic resonance imaging for assessment of presence, size and extent of invasive cervical cancer. Ultrasound in Obstetrics and Gynecology, 2009, 34, 335-344.	1.7	76
6	lmaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcoma. Ultrasound in Obstetrics and Gynecology, 2019, 54, 676-687.	1.7	69
7	Sonographic features of decidualized ovarian endometriosis suspicious for malignancy. Ultrasound in Obstetrics and Gynecology, 2004, 24, 578-580.	1.7	61
8	Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. British Journal of Cancer, 2003, 89, 1180-1184.	6.4	58
9	Ultrasound features of different histopathological subtypes of borderline ovarian tumors. Ultrasound in Obstetrics and Gynecology, 2005, 26, 644-650.	1.7	56
10	Ovarian cancer arising in endometrioid cysts: ultrasound findings. Ultrasound in Obstetrics and Gynecology, 2011, 38, 99-106.	1.7	51
11	Ultrasound evaluation of intraâ€∎bdominal sites of disease to predict likelihood of suboptimal cytoreduction in advanced ovarian cancer: a prospective study. Ultrasound in Obstetrics and Gynecology, 2012, 39, 99-105.	1.7	47
12	Imaging in gynecological disease (12): clinical and ultrasound features of invasive and nonâ€invasive malignant serous ovarian tumors. Ultrasound in Obstetrics and Gynecology, 2017, 50, 788-799.	1.7	42
13	Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer) Tj ETQq1 1	. 0 <b>.ī7.</b> 84314	⊧rgBT /Overl
14	Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. Gynecologic Oncology, 2005, 98, 267-273.	1.4	39
15	Endometrial cancer off-line staging using two-dimensional transvaginal ultrasound and three-dimensional volume contrast imaging: Intermethod agreement, interrater reliability and diagnostic accuracy. Gynecologic Oncology, 2018, 150, 438-445.	1.4	35
16	Does quantitative analysis of three-dimensional power Doppler angiography have a role in the diagnosis of malignant pelvic solid tumors? A preliminary study. Ultrasound in Obstetrics and Gynecology, 2005, 26, 67-72.	1.7	34
17	A prospective blinded comparison of the accuracy of transvaginal sonography and frozen section in the assessment of myometrial invasion in endometrial cancer. Gynecologic Oncology, 2012, 124, 549-552.	1.4	33
18	Lymph Node Involvement in Locally Advanced Cervical Cancer Patients Administered Preoperative Chemoradiation versus Chemotherapy. Annals of Surgical Oncology, 2007, 14, 1129-1135.	1.5	31

Manuela Ludovisi

#	Article	IF	CITATIONS
19	Frozen section examination of pelvic lymph nodes in endometrial and cervical cancer: accuracy in patients submitted to neoadjuvant treatments. Gynecologic Oncology, 2004, 94, 779-784.	1.4	30
20	Imaging in gynecological disease (9): clinical and ultrasound characteristics of tubal cancer. Ultrasound in Obstetrics and Gynecology, 2014, 43, 328-335.	1.7	28
21	The role of sonographic examination in the follow-up of gynecological neoplasms. Gynecologic Oncology, 2005, 99, 696-703.	1.4	25
22	Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Annals of Oncology, 2007, 18, 1348-1353.	1.2	22
23	The sonographic prediction of invasive carcinoma in unilocular-solid ovarian cysts in premenopausal patients: a pilot study. Human Reproduction, 2012, 27, 2676-2683.	0.9	19
24	Agreement of twoâ€dimensional and threeâ€dimensional transvaginal ultrasound with magnetic resonance imaging in assessment of parametrial infiltration in cervical cancer. Ultrasound in Obstetrics and Gynecology, 2015, 45, 459-469.	1.7	19
25	Assessment of pathological status of lower pelvic nodes to tailor surgery in not squamous early cervical carcinoma. Gynecologic Oncology, 2005, 99, 246-247.	1.4	18
26	Ultrasound diagnosis of serous surface papillary borderline ovarian tumor: A case series with a review of the literature. Journal of Clinical Ultrasound, 2015, 43, 573-577.	0.8	17
27	Prognostic role of Ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Gynecologic Oncology, 2008, 109, 187-193.	1.4	16
28	Ultrasound and color power Doppler in the detection of metastatic omentum: a prospective study. Ultrasound in Obstetrics and Gynecology, 2005, 27, 65-70.	1.7	14
29	Clinical and ultrasound characteristics of surgically removed adnexal lesions with largest diameter â‰ <b>¤</b> €‰2.5 cm: a pictorial essay. Ultrasound in Obstetrics and Gynecology, 2017, 50, 648-656.	1.7	13
30	Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. OncoTargets and Therapy, 2014, 7, 1273.	2.0	9
31	Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?. Gynecologic Oncology, 2008, 108, 220-225.	1.4	4
32	Re: Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening ( <scp>UKCTOCS</scp> ). Ultrasound in Obstetrics and Gynecology, 2014, 43, 600-600.	1.7	2
33	Uterine perforation and small bowel incarceration 11 months after dilatation and curettage: sonographic and surgical findings. Ultrasound in Obstetrics and Gynecology, 2017, 49, 278-278.	1.7	2
34	OP05.10: Transvaginal ultrasonography and magnetic resonance in the evaluation of invasive cervical cancer. Ultrasound in Obstetrics and Gynecology, 2008, 32, 328-328.	1.7	1
35	OC25.02: The role of sonographic examination in the follow up of gynecological neoplasms. Ultrasound in Obstetrics and Gynecology, 2005, 26, 349-349.	1.7	0
36	P22.03: Ultrasound and color power Doppler examination in the detection of metastatic omentum: a prospective study. Ultrasound in Obstetrics and Gynecology, 2006, 28, 614-614.	1.7	0

#	Article	IF	CITATIONS
37	OC131: Preoperative local-regional staging of endometrial cancer: transvaginal sonography versus magnetic resonance imaging. Ultrasound in Obstetrics and Gynecology, 2007, 30, 407-407.	1.7	Ο
38	OC25.03: Assessment of myometrial invasion in endometrial cancer by transvaginal sonography and frozen section. Ultrasound in Obstetrics and Gynecology, 2010, 36, 45-45.	1.7	0
39	Ultrasound appearance of breast cancer metastatic to uterine leiomyoma. Ultrasound in Obstetrics and Gynecology, 2018, 51, 839-840.	1.7	0